MarketCap
Facebook
X
Telegram
Fresenius Medical Care AG & Co. KGaA Financial Ratios 2025-2008 | FMS
Brief overview of Fresenius Medical Care AG & Co. KGaA's market valuation
The comparison uses the five latest available annual observations between 2021 and 2025.
The valuation comparison uses P/E 5.74x (median 7.76x), EV/EBITDA 6.6x (median 7.55x), P/S 0.35x (median 0.36x). On average, this basket is 12.6% below its own five-year medians. The market values the business at a discount to recent history.
The inverse P/E implies an earnings yield of 17.4%. This is not a dividend yield, but current earnings relative to market price.
Returns on assets and capital are represented by ROE 8.3%, ROA 3.8%, ROCE 7.4%. Profitability sends a weak positive signal and leaves the business sensitive to cost or demand pressure.
On PEG (0.4x), valuation is restrained relative to growth, but one ratio cannot replace cash-flow and risk analysis.
The cash return period is stable at 106.7 days initially and 113.1 days at the end.
What the ratios show
Fresenius Medical Care AG & Co. KGaA's multiples look low against history, but fundamental returns do not yet provide convincing support.
Annual Financial Ratios Fresenius Medical Care AG & Co. KGaA
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
5.7 | 9.5 | 7.8 | 7.9 | 7.8 | 17.6 | 18.6 | 11.5 | 23.7 | 17.8 | 24.5 | 22.2 | 23.0 | 20.5 | 22.0 | - | - | - |
P/S |
0.3 | 0.4 | 0.3 | 0.4 | 0.5 | 1.1 | 1.3 | 1.4 | 1.7 | 1.2 | 1.5 | 1.5 | 1.7 | 1.8 | 1.8 | - | - | - |
EPS |
3.4 | 1.8 | 1.7 | 2.3 | 3.3 | 4.0 | 4.0 | 6.5 | 4.2 | 3.7 | 3.1 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
22 B | 23.7 B | 23.4 B | 26.1 B | 28.4 B | 38.7 B | 41.1 B | 33.9 B | 42.5 B | 38.7 B | 40.8 B | 35.1 B | 31.6 B | 31.6 B | 30.2 B | 7.44 B | 6.28 B | 8.1 B |
EBITDA per Share |
11.4 | 10.7 | 10.6 | 11.4 | 11.9 | 6.76 | 6.38 | 6.24 | 5.05 | 5.21 | 4.53 | 3.98 | 3.42 | 3.43 | 3.36 | - | - | - |
EV/EBITDA |
6.6 | 7.5 | 7.5 | 7.8 | 8.1 | 7.8 | 8.3 | 9.2 | 13.5 | 9.9 | 12.5 | 12.3 | 13.2 | 13.1 | 13.2 | - | - | - |
PEG |
0.4 | 0.67 | 0.53 | 0.38 | 0.37 | 2.01 | 1.81 | 0.87 | 2.83 | 0.71 | 2.83 | 2.94 | -2.29 | 2.67 | 1.87 | - | - | - |
P/B |
0.5 | 0.4 | 0.4 | 0.5 | 0.7 | 1.7 | 1.7 | 1.8 | 2.8 | 1.9 | 2.4 | 2.3 | 2.7 | 2.6 | 2.9 | - | - | - |
P/CF |
2.5 | 2.9 | 2.2 | 3.3 | 3.8 | 4.8 | 8.7 | 11.0 | 13.8 | 23.4 | 29.4 | 29.3 | 23.3 | 21.0 | 32.6 | - | - | - |
ROE % |
8.34 | 4.70 | 4.94 | 5.79 | 8.72 | 9.44 | 9.07 | 15.36 | 11.82 | 10.85 | 9.81 | 10.42 | 11.70 | 12.89 | 13.29 | - | - | - |
ROA % |
3.84 | 2.21 | 2.16 | 2.50 | 3.55 | 3.67 | 3.64 | 7.55 | 5.33 | 4.62 | 4.03 | 4.11 | 4.80 | 5.32 | 5.48 | - | - | - |
ROCE % |
7.38 | 4.99 | 4.92 | 5.16 | 6.83 | 9.03 | 17.16 | 15.21 | 12.62 | 11.75 | 10.75 | 10.15 | 11.35 | 11.30 | 13.39 | - | - | - |
Current Ratio |
1.9 | 1.9 | 1.8 | 1.8 | 1.7 | 1.6 | 1.7 | 2.0 | 1.8 | 1.5 | 1.7 | 1.9 | 1.8 | 1.9 | 1.3 | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | 88.9 | 90.6 | 93.1 | 91.3 | 90.3 | 83.0 | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | 42.4 | 42.9 | 37.6 | 40.6 | 41.1 | 42.7 | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | 18.3 | 20.1 | 19.3 | 20.1 | 24.7 | 23.9 | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | 131.3 | 133.5 | 130.7 | 131.8 | 131.4 | 125.7 | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | 113.1 | 113.4 | 111.4 | 111.8 | 106.7 | 101.8 | - | - | - |
All numbers in EUR currency
Quarterly Financial Ratios Fresenius Medical Care AG & Co. KGaA
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q4 | 2009-Q3 | 2009-Q2 | 2008-Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
3.36 | 0.94 | 0.77 | 0.52 | 1.83 | 0.73 | 0.64 | 0.24 | 1.7 | 0.29 | 0.48 | 0.29 | - | - | - | 0.54 | - | 0.93 | 0.75 | 0.85 | - | 1.21 | 1.2 | 0.95 | - | 1.1 | 0.84 | 0.88 | - | 0.93 | 3.24 | 0.91 | - | 1.01 | 0.88 | 1.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
11.4 | 5.49 | 4.07 | 2.47 | 10.7 | 5.89 | 4.51 | 2.58 | 10.6 | 5.62 | 4.19 | 2.38 | - | - | - | 2.62 | - | 1.72 | 1.45 | 2.94 | - | 2.16 | 2.24 | 3.21 | - | 1.98 | 1.72 | 2.93 | - | 1.72 | 4.57 | 1.62 | - | 1.99 | 1.9 | 2.12 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
13.82 | 10.18 | 9.61 | 9.29 | 8.85 | 9.09 | 8.26 | 7.98 | 8.08 | 4.59 | 6.11 | 6.98 | 6.10 | 6.10 | 6.10 | 8.41 | 6.95 | 10.27 | 11.01 | 11.47 | 9.16 | 12.05 | 11.19 | 10.47 | 7.83 | 10.65 | 16.57 | 16.86 | 14.38 | 17.86 | 18.20 | 12.91 | 10.16 | 3.48 | 3.16 | 3.53 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
6.35 | 4.72 | 4.47 | 4.31 | 4.07 | 4.02 | 3.63 | 3.47 | 3.51 | 1.96 | 2.52 | 2.81 | 2.44 | 2.44 | 2.44 | 3.35 | 2.74 | 4.01 | 4.28 | 4.46 | 3.55 | 4.73 | 4.44 | 4.21 | 3.18 | 4.54 | 7.57 | 7.95 | 6.94 | 8.47 | 8.47 | 5.72 | 4.36 | 1.53 | 1.37 | 1.46 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
12.15 | 9.76 | 9.60 | 9.46 | 9.12 | 9.05 | 8.43 | 8.17 | 8.20 | 4.50 | 5.30 | 5.70 | 4.80 | 4.80 | 4.80 | 6.63 | 5.41 | 7.83 | 8.43 | 8.95 | 7.12 | 9.43 | 9.11 | 8.74 | 6.56 | 9.26 | 14.12 | 14.52 | 12.37 | 18.08 | 20.83 | 19.76 | 17.25 | 5.70 | 5.46 | 6.09 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.9 | 1.8 | 1.8 | 1.9 | 1.9 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | - | - | - | 1.7 | 1.7 | 1.7 | 1.6 | 1.7 | 1.6 | 1.6 | 1.6 | 1.6 | 1.7 | 1.7 | 1.7 | 1.7 | 2.0 | 1.9 | 1.9 | 1.8 | 1.8 | - | - | - | 1.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Multiples are an important financial analysis tool for the company Fresenius Medical Care AG & Co. KGaA, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
China
USA
Russia
Britain
